Arovella Therapeutics Ltd has released a press release.
iNKT cell therapy platform update
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- SUDA appoints new cell and gene therapy manufacturing expert
- Disclosure Document Prospectus $3.65m
- SUDA Placement Raises $3.65m
- Investor Presentation incorporating iNKT Cell Platform
- SUDA Licenses a Novel iNKT Cell Therapy Platform
Later from Arovella Therapeutics
- ZolpiMist Update
- SUDA signs Licence and Distribution Agreement with STADA
- Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB
- GM presentation
- Chile Ministry of Health Approval Granted for ZolpiMist
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics